Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis

NCT05634746 is registered in ClinicalTrials.gov with Ellodi Pharmaceuticals, LP as lead sponsor.

NCT NCT05634746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05634746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis
Lead sponsor
Ellodi Pharmaceuticals, LP
Phase
Phase 3
Overall status
Completed
Start date
December 29, 2022
Completion date
August 12, 2024
Enrollment
218 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis